Peter Chen

Peter Chen is a Senior Scientist I at Prime Medicine, Inc., with extensive experience in genome editing, RNA modification systems, and patent filing. Previously, Peter was a Ph.D. student at Harvard University, where Peter conducted research in the David Liu Group. As a Fulbright Scholar at EPFL, Peter focused on directed evolution of cyclic peptide protease inhibitors. Their undergraduate research at the University of Chicago explored bacterial signal transduction systems and post-transcriptional RNA modifications. Peter holds a Ph.D. in Chemical Biology from Harvard University and a Bachelor of Science in Chemistry and Biochemistry from the University of Chicago.